

<b>Table S1. Literature Review</b>												
<b>Author</b>	<b>Year</b>	<b>Study design/ location</b>	<b>Endpoints</b>	<b># Cohort</b>	<b># Cases</b>	<b>Exact exposure</b>	<b>Exposure characterization</b>	<b>Measure of associations</b>	<b>P for trend</b>			
<i>Omega-6/omega-3 ratio</i>												
Noori et al. <sup>1</sup>	2011	Prospective cohort/ hemodialysis patients, Southern California during 2001-2007	All-cause mortality	145	42	Dietary Omega-3 Dietary Omega-6/3	HR in quartiles (95% CI)	(Highest to lowest) 0.65 (0.21-1.97) (Lowest to highest) 0.37 (0.14-1.08)	0.1 0.04			
Harris et al. <sup>2</sup>	2017	Prospective cohort/ women, Women's Health Initiative Memory Study, enrollment began 1996, age 65-80	All-cause mortality	6,501	1,851	Red blood cell Omega-3 index (EPA + DHA) EPA DHA LA N-6/N-3 ratio	HR per 1-SD increase in red blood cell PUFA (99% CI)	All Omega-3 index: 0.92 (0.85-0.98) EPA: 0.89 (0.82-0.96) DHA: 0.93 (0.87-1.00) LA: 0.99 (0.93-1.06) N-6/N-3 ratio: 1.10 (1.02-1.19)	0.0015 < 0.001 0.0099 0.8286 0.0021 NR			
			CVD mortality							617	CVD Omega-3 index: 0.97 (0.85-1.12) EPA: 0.88 (0.77-1.00) DHA: 1 (0.87-1.14) LA: 0.96 (0.86-1.08) N-6/N-3 ratio: 1.05 (0.9-1.23)	NR
			Cancer mortality							462	Cancer Omega-3 index: 0.92 (0.79-1.07) EPA: 0.91 (0.78-1.07) DHA: 0.93 (0.79-1.09) LA: 0.94 (0.83-1.07) N-6/N-3 ratio: 1.1 (0.93-1.3)	
Otsuka et al. <sup>3</sup>	2019	Prospective cohort study/ NILS-LSA, elderly individuals, Japan	All-cause mortality	1054	422	n-6 intake n-3 intake EPA intake DHA intake Serum EPA Serum DHA Serum EPA/ARA	HR in tertiles (Highest to lowest; 95% CI)	0.80 (0.59-1.07) 0.83 (0.61-1.12) 0.96 (0.71-1.30) 0.95 (0.70-1.28) 0.81 (0.60-1.09) 0.73 (0.53-0.99) 0.71 (0.53-0.96)	0.13 0.22 0.78 0.72 0.17 0.047 0.02			
Zhuang et al. <sup>4</sup>	2019	Population based prospective cohort/ CHNS in China and NHANES in US	All-cause mortality	CHNS: 14,117 NHANES: 36,032	1,007 4,826	Total PUFA intake  Omega-3 intake  Omega-6 intake  Omega 6/3 ratio	HR in quartiles (Highest to lowest; 95% CI)	China: 1.19 (0.93-1.52) US: 0.86 (0.71-1.03) China: 1.22 (1.00-1.50) US: 0.85 (0.71-1.01) China: 1.14 (0.89-1.47) US: 0.84 (0.70-1.01) China: 0.95 (0.80-1.14) US: 0.99 (0.89-1.11)	0.10 0.05 0.05 0.03 0.29 0.04 0.54 0.85			
<i>Circulating PUFAs</i>												
Wang et al. <sup>5</sup>	2003	An epidemiological survey of 65 rural countries in China	All-cause mortality	6500	NR	DHA EPA Total plasma Omega-3 Total plasma Omega-6	Pearson correlation coefficient	Around -0.3 (mortality) Around -0.2 (mortality) -0.152 -0.001	NR			

Lindberg et al. <sup>6</sup>	2008	Prospective cohort/ Norway, elderly patients (mean=82.1), 3 y of follow-up	All-cause mortality	254	101	Plasma EPA	HR for quantile 1 (lowest, ref; 95% CI) compared with upper 3 quartiles combined	0.52 (0.35-0.77)	NR
Chattipakorn et al. <sup>7</sup>	2009	Measure the heart tissues of cadavers with a history of CHD	-	100 cadavers	-	Omega-3 (EPA + DHA) Omega-6 (AA + LA)	P-value from two-sample Wilcoxon rank sum test (cardiac cause vs. noncardiac cause. Lower in the group with cardiac mortality)	Cadavers with heart disease 0.040 0.022	NR
Lee et al. <sup>8</sup>	2009	Prospective cohort/ patients with acute myocardial infarction, 16.1 months follow-up	All-cause mortality	508	36	Plasma EPA	-	Lower plasma level of EPA was and independent predictor for all-cause mortality in female patients	NR
Pottala et al. <sup>9</sup>	2010	Prospective cohort/ outpatients with stable coronary heart disease, recruited between 2000-2002, San Francisco Bay Area	All-cause mortality	956	237	EPA + DHA in whole blood	HR above vs. below median (95% CI)	0.74 (0.55-1.00)	0.049
Petrone et al. <sup>10</sup>	2012	Nested case-control/ US male physicians	Heart failure	788 cases 788 matched controls	-	Plasma omega-6 PUFAs	OR in quartiles (Highest to lowest; 95% CI)	0.87 (0.63-1.20)	0.39
Mozaffarian et al. <sup>11</sup>	2013	Prospective cohort/ older adults not taking fish oil supplements, 1992-2008, four US communities	All-cause mortality CVD mortality	2,692	1,625 570	Plasma Total n-3 PUFA	HR in quintiles (Highest to lowest; 95% CI)	0.73 (0.61-0.86) 0.65 (0.48-0.87)	<0.001 < 0.001
Wu et al. <sup>12</sup>	2014	Community-based prospective cohort/ Cardiovascular Health Study, age>=65, US	All-cause mortality CVD mortality	2,792	1,994 678	Plasma phospholipid n-6 PUFA LA (Others are NS)	HR in quintiles (Highest to lowest; 95% CI)	All-cause mortality 0.87 (0.74-1.02) CVD mortality 0.78 (0.60-1.01)	0.005 0.02
Eide et al. <sup>13</sup>	2016	Cross-sectional study/ Renal transplant recipients, transplanted 1999-2011	CVD mortality	1990	NR	plasma Marine n-3 PUFA levels	Per 1.0 wt% increase (95% CI)	0.90 (0.82-0.98)	NR
Kleber et al. <sup>14</sup>	2016	Prospective cohort/ patients referred for coronary angiography, LURIC study, German	All-cause mortality CVD mortality	3259	975 614	erythrocytes (red cells) EPA HS-Omega-3 Index	HR in tertiles (Highest to lowest; 95% CI)	EPA All: 0.75 (0.64-0.88) CVD: 0.70 (0.57-0.86) HS-Omega-3 Index All: 0.78 (0.67-0.92) CVD: 0.78 (0.64-0.95)	0.001 0.003 0.009 0.050
Miura et al. <sup>15</sup>	2016	Population based prospective cohort/ Austria, drawn from Nambour Skin Cancer Study, in 1986	All-cause mortality	1,008	179 M: 98 F: 81	Plasma total Omega-3  EPA  DPA  DHA  Total Omega-6	HR per 1-SD increase (95% CI)	All: 0.96 (0.82-1.12) M: 0.99 (0.80-1.22) F: 0.95 (0.76-1.19) All: 0.81 (0.69-0.95) M: 0.78 (0.62-0.98) F: 0.78 (0.65-0.94) All: 0.90 (0.77-1.05) M: 0.76 (0.60-0.97) F: 0.98 (0.79-1.22) All: 1.07 (0.92-1.25) M: 1.12 (0.92-1.36) F: 1.02 (0.82-1.28) All: 0.87 (0.73-1.04) M: 0.80 (0.92-1.04) F: 0.96 (0.76-1.21)	0.62 0.90 0.66 0.012 0.036 0.007 0.08 0.028 0.86 0.35 0.25 0.83 0.13 0.10 0.71
Chen et al. <sup>16</sup>	2016	Meta-analysis/ general populations	All-cause mortality	11 studies 371,965	31,185		Summary RR (Highest to lowest; 95% CI)		NR

(Included Mozaffarian et al. and Bell et al. reports in the table)				Dietary intakes (n=7) 361,273 Circulating levels (n=4) 10,692	27,624  3,561	Circulating EPA Circulating DHA		0.74 (0.60-0.90) 0.78 (0.64-0.93)	
Delgado et al. <sup>17</sup>	2017	Prospective cohort/ patients referred for coronary angiography, LURIC study, German	All-cause mortality CVD mortality	3259	975 614	Plasma total omega-6 PUFA  GLA ADA DPA	1 SD increase (95 % CI)	All: 0.93 (0.87-0.99) CVD: 0.95 (0.87-1.03)  All: 0.88 (0.82-0.95) CVD: 0.86 (0.79-0.95) All: 1.10 (1.03-1.18) CVD: 1.12 (1.04-1.22) All: 1.12 (1.05-1.19) CVD: 1.11 (1.02-1.20)	NR
Hamazaki et al. <sup>18</sup>	2018	Nested case-control study/ JPHC study, Japan	Coronary heart disease	209 cases 418 matched controls	(168 myocardial infarction 41 sudden cardiac death) (157 non-fatal coronary events 52 fatal)	Plasma n-3 PUFAs	OR in quartiles (Highest to lowest; 95% CI)	CHD:0.79 (0.41-1.51) MI: 0.91 (0.43-1.89) Sudden death: 0.08 (0.01-0.88) Non-fatal: 0.89 (0.42-1.89) Fatal: 0.12 (0.02-0.75)	0.51 0.90 0.04 0.97 0.03
Harris et al. <sup>19</sup>	2018	Prospective cohort study/ the Framingham Heart Study Offspring cohort, US	All-cause mortality CVD mortality Cancer mortality CVD events	2500	350 58 146 245	Omega-3 index red blood cells	HR in quintiles (Highest to lowest; 95% CI)	All-death: 0.66 (0.45-0.96) CVD mortality: 0.39 (0.15-1.02) Cancer mortality: 0.96 (0.56-1.64) CVD events: 0.61 (0.37-0.99)	0.02 0.10 0.88 0.008
Kamleh et al. <sup>20</sup>	2018	Case-control study/ IMPROVE pan-European cohort, age 55-79	Incidence of CVD events	Cases: 173 Matched controls: 172 Diabetics Cases: 40 Matched controls: 39 Non-diabetics Cases: 133 Matched controls: 133	-	Plasma DHA  GLA AA ADA	HR per 1-SD increase in log transformed metabolite concentration (95% CI)	Diabetics: NS Non-diabetics: DHA: 0.86 (0.72-1.02)  GLA: 0.72 (0.59-0.88) AA: 0.83 (0.70-0.99) ADA: 0.79 (0.66-0.95)	0.085  0.001 0.037 0.012
Miura et al. <sup>21</sup>	2018	Community-based prospective cohort/ women, 25-75 age, Australia	All-cause mortality	564	81	Plasma Omega-3 Omega-6	HR in tertiles (Highest to lowest; 95% CI)	Absolute (ug/ml) Omega-3: 1.05 (0.57-1.92) Omega-6: 1.19 (0.65-2.18) Relative (%) Omega-3: 0.97 (0.54-1.72) Omega-6: 1.02 (0.58-1.78)	0.84 0.60 0.77 1.00
Marklund et al. <sup>22</sup>	2019	Meta-analysis	Total CVD CVD mortality Total CHD Ischemic stroke	30 prospective studies:  18 cohort 12 nested case-control or	10,477 4,508 11,857 3,705	Circulating LA  AA	HR per interquintile range (95% CI)	LA Total CVD: 0.93 (0.88-0.99) CVD mortality: 0.78 (0.70-0.85) Total CHD: 0.94 (0.88-1.00) Ischemic stroke: 0.88 (0.79-0.98)	NR

				case-control				AA Total CVD: 0.95 (0.90-1.01) CVD mortality: 0.94 (0.86-1.02) Total CHD: 0.99 (0.94-1.04) Ischemic stroke: 0.99 (0.90-1.10)	
Harris et al. <sup>23</sup>	2020	Case-cohort study/ secondary analysis of ADVANCE study, patients with type 2 diabetes	Macrovascular disease Microvascular disease All-cause mortality CVD mortality	3,576	654 341 631 330	Plasma Omega-3 Omega-6	HR per 1-SD increase of the percentage contribution of total fatty acids (95% CI)	Macrovascular disease Omega-3: 0.87 (0.80-0.95) Omega-6: 0.97 (0.89-1.07) Microvascular disease Omega-3: 1.01 (0.91-1.13) Omega-6: 0.97 (0.86-1.10) All-cause mortality Omega-3: 0.91 (0.84-0.99) Omega-6: 0.97 (0.88-1.07) CVD mortality Omega-3: 0.85 (0.75-0.96)	NR
Harris et al. <sup>24</sup>	2021	Meta-analysis/ age 50-81	All-cause mortality CVD mortality Cancer mortality	All: 17 cohorts, 42,466 CVD: 15 cohorts Cancer: 15 cohorts	15,720  4,571  4,284	Serum EPA  DPA  DHA  EPA+DHA	HR in quintiles (Highest to lowest; 95% CI)	EPA All: 0.82 (0.78-0.87) CVD: 0.85 (0.77-0.94) Cancer: 0.82 (0.74-0.91) DPA All: 0.84 (0.79-0.90) CVD: 0.87 (0.78-0.98) Cancer: 0.79 (0.70-0.90) DHA All: 0.85 (0.81-0.90) CVD: 0.79 (0.72-0.88) Cancer: 0.86 (0.78-0.95) EPA+DHA All: 0.84 (0.79-0.89) CVD: 0.80 (0.73-0.88) Cancer: 0.87 (0.78-0.96)	<0.001 0.006 0.008  <0.001 0.16 0.008  0.01 0.002 0.06  <0.001 <0.001 0.06
Kamalita et al. <sup>25</sup>	2021	Prospective cohort/ patients with prior MI, 60-80 years old, Dutch	All-cause mortality CVD mortality	4,067	1,877 834	Circulating EPA + DHA	HR in quintiles (Highest to lowest; 95% CI)	0.73 (0.63-0.86) 0.75 (0.60-0.95)	<0.001 0.016
Diffenderfer et al. <sup>26</sup>	2022	Plasma fatty acid profiles in US	Heart disease mortality rate	1,169,621	NR	Plasma EPA Omega-3 index	Pearson correlation coefficient	-0.504 -0.570	<0.001 <0.001
<i>Dietary PUFAs</i>									
Bell et al. <sup>27</sup>	2014	Population based prospective cohort/ VITAL Study, 50-76 yrs old, western Washington State, recruited 2000-2002	All-cause mortality CVD mortality Cancer mortality	70,495	3,051 769 1,485	EPA + DHA intake (diet + supplements)	HR in quartiles (Highest to lowest; 95% CI)	0.82 (0.73-0.93) 0.87 (0.68-1.10) 0.77 (0.64-0.92)	0.001 0.158 0.001
Chen et al. <sup>16</sup> (Included Mozaffarian et al. and Bell et al. reports in the table)	2016	Meta-analysis/ general populations	All-cause mortality	11 studies 371,965 Dietary intakes (n=7) 361,273 Circulating levels (n=4) 10,692	31,185  27,624  3,561	N-3 LCPUFA intake	Summary RR (Highest to lowest; 95% CI)	0.91 (0.84-0.98)	NR

Zhang et al. <sup>28</sup>	2018	Population based prospective cohort/ NIH-AARP Diet and Health Study, US	All-cause mortality CVD mortality Cancer mortality	421,309 M: 240,729 F: 180,580	All M: 54,230 F: 30,882 CVD M: 14,824 F: 7,541 Cancer M: 20,041 F: 11,526	Long-chain omega-3 PUFA intake	HR in quintiles (Highest to lowest; 95% CI)	All M: 0.89 (0.86-0.92) F: 0.90 (0.86-0.94) CVD: M: 0.85 (0.80-0.90) F: 0.82 (0.75-0.90) Cancer: M: 0.95 (0.90-1.00) F: 1.01 (0.93-1.09)	< 0.001 < 0.001 <0.001 < 0.001 0.04 0.51
Kamalita et al. <sup>25</sup>	2021	Prospective cohort/ patients with prior MI, 60-80 years old, Dutch	All-cause mortality CVD mortality	4,067	1,877 834	Dietary EPA + DHA intake	HR in quintiles (Highest to lowest; 95% CI)	All: 0.86 (0.75-0.99) CVD: 0.84 (0.68-1.04)	0.11 0.22
<i>Fish intake and fish oil supplementation</i>									
Nagata et al. <sup>29</sup>	2002	Population based prospective cohort/ Japan, age >= 35, 1992-1999	All-cause mortality CVD mortality Cancer mortality	29,079 M: 13,355 F: 15,724	2,062 M: 1,163 F: 899 635 M: 308 F: 327 653 M: 400 F: 253	Fish oil	HR in quintiles (Highest to lowest; 95% CI)	M: 0.87 (0.73-1.05) F: 0.77 (0.62-0.94)  M: 0.76 (0.54-1.07) F: 0.77 (0.55-1.00)  M: 0.89 (0.66-1.20) F: 0.70 (0.47-1.05)	0.38 0.01  0.27 0.16  0.52 0.15
Li et al. <sup>30</sup>	2020	Population based prospective cohort/ UK biobank	All-cause mortality CVD mortality	427,678	12,928 3282	Fish oil supplementation	HR (Yes to No; 95% CI)	0.87 (0.83-0.90) 0.84 (0.78-0.91)	NR
Jayedti et al. <sup>31</sup>	2021	Meta-analysis/ patients with type 2 diabetes	All-cause mortality CVD diseases CHD MI stroke	Total: 9 studies (57,394) 8 studies (57,077) 4 studies (8781)	NR  791 376 372	Fish consumption	Pooled RR (Highest to lowest; 95% CI)	0.86 (0.76-0.96)  0.61 (0.29-0.93) NS NS	NR
Liu et al. <sup>32</sup>	2022	Population based prospective cohort/ UK Biobank, UK	Overall cancer	470,804	28,417	Fish oil supplementation	HR (Yes to No; 95% CI)	0.97 (0.95-1.00)	0.06
Ma et al. <sup>33</sup>	2022	Prospective cohort/ patients with hypertension, UK Biobank, UK	Incidence of cardiometabolic multimorbidity (CMM) All-cause mortality CVD mortality Cancer mortality	81,579	15,990  6,456 1,308 3,307	Fish oil supplementation	HR (Yes to No; 95% CI)	0.92 (0.89-0.96)  0.90 (0.85-0.95) 0.86 (0.76-0.98) 0.99 (0.91-1.07)	<0.001  0.027 0.742
Abbreviations: HR, hazards ratio; NR, not recorded; NS, not significant.									

## References

- Noori N, Dukkipati R, Kovesdy CP, et al. Dietary omega-3 fatty acid, ratio of omega-6 to omega-3 intake, inflammation, and survival in long-term hemodialysis patients. *Am J of Kidney Dis.* 2011;58(2):248-256.
- Harris WS, Luo J, Pottala JV, et al. Red blood cell polyunsaturated fatty acids and mortality in the Women's Health Initiative Memory Study. *J Clin Lipidol.* 2017;11(1):250-259.e255.
- Otsuka R, Tange C, Nishita Y, et al. Fish and meat intake, serum eicosapentaenoic acid and docosahexaenoic acid levels, and mortality in community-dwelling Japanese older persons. *Int J Environ Res Public Health.* 2019;16(10).

4. Zhuang P, Wang W, Wang J, Zhang Y, Jiao J. Polyunsaturated fatty acids intake, omega-6/omega-3 ratio and mortality: Findings from two independent nationwide cohorts. *Clin Nutr*. 2019;38(2):848-855.
5. Wang Y, Crawford MA, Chen J, et al. Fish consumption, blood docosahexaenoic acid and chronic diseases in Chinese rural populations. *Comp Biochem Physiol A Mol Integr Physiol*. 2003;136(1):127-140.
6. Lindberg M, Saltvedt I, Sletvold O, Bjerve KS. Long-chain n-3 fatty acids and mortality in elderly patients. *Am J Clin Nutr*. 2008;88(3):722-729.
7. Chattipakorn N, Settakorn J, Petsophonakul P, et al. Cardiac mortality is associated with low levels of omega-3 and omega-6 fatty acids in the heart of cadavers with a history of coronary heart disease. *Nutr Res*. 2009;29(10):696-704.
8. Lee S-H, Shin M-J, Kim J-S, et al. Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction—data from Infarction Prognosis Study (IPS) Registry. *Circ J*. 2009;73(12):2250-2257.
9. Pottala JV, Garg S, Cohen BE, Whooley MA, Harris WS. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: the Heart and Soul study. *Circ Cardiovasc Qual Outcomes*. 2010;3(4):406-412.
10. Petrone AB, Weir N, Hanson NQ, et al. Omega-6 fatty acids and risk of heart failure in the Physicians' Health Study. *Am J Clin Nutr*. 2012;97(1):66-71.
11. Mozaffarian D, Lemaitre RN, King IB, et al. Plasma phospholipid long-chain  $\omega$ -3 fatty acids and total and cause-specific mortality in older adults: a cohort study. *Ann Intern Med*. 2013;158(7):515-525.
12. Wu JHY, Lemaitre RN, King IB, et al. Circulating omega-6 polyunsaturated fatty acids and total and cause-specific mortality. *Circulation*. 2014;130(15):1245-1253.
13. Eide IA, Dahle DO, Svensson M, et al. Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients. *Eur J Clin Nutr*. 2016;70(7):824-830.
14. Kleber ME, Delgado GE, Lorkowski S, März W, von Schacky C. Omega-3 fatty acids and mortality in patients referred for coronary angiography. The Ludwigshafen Risk and Cardiovascular Health Study. *Atherosclerosis*. 2016;252:175-181.
15. Miura K, Hughes MCB, Ungerer JPJ, Green AC. Plasma eicosapentaenoic acid is negatively associated with all-cause mortality among men and women in a population-based prospective study. *Nutr Res*. 2016;36(11):1202-1209.
16. Chen GC, Yang J, Eggersdorfer M, Zhang W, Qin LQ. N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis. *Sci Rep*. 2016;6:28165.
17. Delgado GE, März W, Lorkowski S, von Schacky C, Kleber ME. Omega-6 fatty acids: opposing associations with risk—The Ludwigshafen Risk and Cardiovascular Health Study. *J Clin Lipidol*. 2017;11(4):1082-1090.e1014.
18. Hamazaki K, Iso H, Eshak ES, et al. Plasma levels of n-3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-based (JPHC) study. *Atherosclerosis*. 2018;272:226-232.
19. Harris WS, Tintle NL, Etherton MR, Vasan RS. Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study. *J Clin Lipidol*. 2018;12(3):718-727.e716.
20. Kamleh MA, McLeod O, Checa A, et al. Increased levels of circulating fatty acids are associated with protective effects against future cardiovascular events in nondiabetics. *J Proteome Res*. 2018;17(2):870-878.
21. Miura K, Hughes MCB, Ungerer JPJ, Smith DD, Green AC. Absolute versus relative measures of plasma fatty acids and health outcomes: example of phospholipid omega-3 and omega-6 fatty acids and all-cause mortality in women. *Eur J Nutr*. 2018;57(2):713-722.
22. Marklund M, Wu JHY, Imamura F, et al. Biomarkers of dietary omega-6 fatty acids and incident cardiovascular disease and mortality. *Circulation*. 2019;139(21):2422-2436.

23. Harris K, Oshima M, Sattar N, et al. Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. *Diabetologia*. 2020;63(8):1637-1647.
24. Harris WS, Tintle NL, Imamura F, et al. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. *Nat Commun*. 2021;12(1):2329.
25. Pertiwi K, Kùpers LK, Goede Jd, Zock PL, Kromhout D, Geleijnse JM. Dietary and circulating long-chain omega-3 polyunsaturated fatty acids and mortality risk after myocardial infarction: a long-term follow-up of the Alpha Omega Cohort. *J Am Heart Assoc*. 2021;10(23):e022617.
26. Diffenderfer MR, Rajapakse N, Pham E, et al. Plasma fatty acid profiles: relationships with sex, age, and state-reported heart disease mortality rates in the United States. *J Clin Lipidol*. 2022;16(2):184-197.
27. Bell GA, Kantor ED, Lampe JW, Kristal AR, Heckbert SR, White E. Intake of long-chain  $\omega$ -3 fatty acids from diet and supplements in relation to mortality. *Am J Epidemiol*. 2014;179(6):710-720.
28. Zhang Y, Zhuang P, He W, et al. Association of fish and long-chain omega-3 fatty acids intakes with total and cause-specific mortality: prospective analysis of 421 309 individuals. *J Intern Med*. 2018;284(4):399-417.
29. Nagata C, Takatsuka N, Shimizu H. Soy and fish oil intake and mortality in a Japanese community. *Am J Epidemiol*. 2002;156(9):824-831.
30. Li Z-H, Zhong W-F, Liu S, et al. Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study. *BMJ*. 2020;368:m456.
31. Jayedi A, Soltani S, Abdolshahi A, Shab-Bidar S. Fish consumption and the risk of cardiovascular disease and mortality in patients with type 2 diabetes: a dose-response meta-analysis of prospective cohort studies. *Crit Rev Food Sci Nutr*. 2021;61(10):1640-1650.
32. Liu Z, Luo Y, Ren J, et al. Association between fish oil supplementation and cancer risk according to fatty fish consumption: A large prospective population-based cohort study using UK Biobank. *Int J Cancer*. 2022;150(4):562-571.
33. Ma T, He L, Luo Y, et al. Associations of baseline use of fish oil with progression of cardiometabolic multimorbidity and mortality among patients with hypertension: a prospective study of UK Biobank. *Eur J Nutr*. 2022.